Drug Information
Drug General Information | Top | |||
---|---|---|---|---|
Drug ID |
D03NHW
|
|||
Former ID |
DAP000655
|
|||
Drug Name |
Ofloxacin
|
|||
Synonyms |
Bactocin; DEXTROFLOXACINE; Danoflox; Effexin; Exocin; Exocine; Flobacin; Flodemex; Flotavid; Flovid; Floxal; Floxil; Floxin; Floxstat; Fugacin; Inoflox; Kinflocin; Kinoxacin; Liflox; Loxinter; Marfloxacin; Medofloxine; Mergexin; Novecin; Nufafloqo; OFLX; OFX; Obide; Occidal; Ocuflox; Ofcin; Oflin; Oflocee; Oflocet; Oflocin; Oflodal; Oflodex; Oflodura; Oflox; Ofloxacina; Ofloxacine; Ofloxacino; Ofloxacinum; Ofloxin; Ofus; Onexacin; Operan; Orocin; Otonil; Oxaldin; Pharflox; Praxin; Puiritol; Qinolon; Qipro; Quinolon; Quotavil; Rilox; Sinflo; Tabrin; Taravid; Tariflox; Tarivid; Telbit; Tructum; Viotisone; Visiren; XED; Zanocin; Floxin otic; Ofloxacin Otic; Ofloxacina [DCIT]; Ofloxacine [French]; Ofloxacino [Spanish]; Ofloxacinum [Latin]; Uro Tarivid; DL 8280; HOE 280; O 8757; ORF 18489; PT 01; DL-8280; FLOXIN IN DEXTROSE 5%; FLOXIN IN DEXTROSE 5% IN PLASTIC CONTAINER; Floxin Otic (TN); HOE-280; Hoe-280; Marfloxacin (TN); O-Flox; ORF-28489; Ocuflox (TN); Ru-43280; WP-0405; Ofloxacin (JP15/USP/INN); Ofloxacin [USAN:BAN:INN:JAN]; Ofloxacin, (S)-Isomer; DL-8280, HOE-280, Exocin, Flobacin, Floxin, Floxil, Monoflocet, Ofloxacin; (+-)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid; (+/-)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperaz inyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid; (+/-)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid; (+/-)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido[1,2,3-de]-1,4-benzoxazine-6-carboxylic acid; (+/-)-Floxin; (-)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)(1,4)benzoxazin-6-carbonsaeure; 9-fluoro-3-methyl-10-(4-methylpiperazin-1-yl)-7-oxo-2,3-dihydro-7H-[1,4]oxazino[2,3,4-ij]quinoline-6-carboxylic acid
Click to Show/Hide
|
|||
Drug Type |
Small molecular drug
|
|||
Indication | Bacterial infection [ICD-11: 1A00-1C4Z; ICD-10: A00-B99] | Approved | [1] | |
Therapeutic Class |
Antibiotics
|
|||
Company |
Janssen Pharmaceutica
|
|||
Structure |
Download2D MOL |
|||
Formula |
C18H20FN3O4
|
|||
Canonical SMILES |
CC1COC2=C3N1C=C(C(=O)C3=CC(=C2N4CCN(CC4)C)F)C(=O)O
|
|||
InChI |
1S/C18H20FN3O4/c1-10-9-26-17-14-11(16(23)12(18(24)25)8-22(10)14)7-13(19)15(17)21-5-3-20(2)4-6-21/h7-8,10H,3-6,9H2,1-2H3,(H,24,25)
|
|||
InChIKey |
GSDSWSVVBLHKDQ-UHFFFAOYSA-N
|
|||
CAS Number |
CAS 82419-36-1
|
|||
PubChem Compound ID | ||||
PubChem Substance ID |
9529, 597127, 3206370, 5025346, 7847519, 7891126, 7980182, 8027636, 8149812, 8152815, 11335896, 11361135, 11364080, 11366642, 11369204, 11372716, 11373806, 11377366, 11462107, 11466265, 11467385, 11485123, 11485970, 11489280, 11491314, 11492139, 11495000, 11533038, 12013736, 14876840, 17405462, 24278613, 24860450, 26612280, 26680409, 26747609, 26747610, 26747611, 26747612, 29223672, 46507574, 47216794, 47291150, 47515336, 47589018, 47589019, 47959764, 48035139, 48259249, 48259250
|
|||
ChEBI ID |
CHEBI:7731
|
|||
ADReCS Drug ID | BADD_D01598 | |||
SuperDrug ATC ID |
J01MA01; S01AE01; S02AA16
|
|||
SuperDrug CAS ID |
cas=082419361
|
Interaction between the Drug and Microbe | Top | |||
---|---|---|---|---|
The Abundace of Studied Microbe(s) Regulated by Drug | ||||
The Order in the Taxonomic Hierarchy of the following Microbe(s): Bacteroidales | ||||
Studied Microbe: Bacteroides
Show/Hide Hierarchy
|
[2] | |||
Hierarchy | ||||
Abundance Change | No significant change | |||
Experimental Species | Human | Experimental Sample | Faeces | |
Disease or Condition | Healthy | |||
Description | The abundance of Bacteroides was not significantly changed by Ofloxacin. | |||
Studied Microbe: Bacteroides caccae
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Bacteroides caccae was decreased by Ofloxacin (adjusted p-values: 5.59E-04). | |||
Studied Microbe: Bacteroides fragilis enterotoxigenic
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Bacteroides fragilis enterotoxigenic was decreased by Ofloxacin (adjusted p-values: 5.19E-04). | |||
Studied Microbe: Bacteroides fragilis nontoxigenic
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Bacteroides fragilis nontoxigenic was decreased by Ofloxacin (adjusted p-values: 7.24E-06). | |||
Studied Microbe: Bacteroides ovatus
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Bacteroides ovatus was decreased by Ofloxacin (adjusted p-values: 9.23E-06). | |||
Studied Microbe: Bacteroides thetaiotaomicron
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Bacteroides thetaiotaomicron was decreased by Ofloxacin (adjusted p-values: 1.31E-05). | |||
Studied Microbe: Bacteroides uniformis
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Bacteroides uniformis was decreased by Ofloxacin (adjusted p-values: 3.19E-03). | |||
Studied Microbe: Bacteroides vulgatus
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Bacteroides vulgatus was decreased by Ofloxacin (adjusted p-values: 7.86E-06). | |||
Studied Microbe: Bacteroides xylanisolvens
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Bacteroides xylanisolvens was decreased by Ofloxacin (adjusted p-values: 2.42E-06). | |||
Studied Microbe: Odoribacter splanchnicus
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Odoribacter splanchnicus was decreased by Ofloxacin (adjusted p-values: 2.98E-04). | |||
Studied Microbe: Parabacteroides distasonis
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Parabacteroides distasonis was decreased by Ofloxacin (adjusted p-values: 6.66E-07). | |||
Studied Microbe: Parabacteroides merdae
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Parabacteroides merdae was decreased by Ofloxacin (adjusted p-values: 4.93E-07). | |||
The Order in the Taxonomic Hierarchy of the following Microbe(s): Bifidobacteriales | ||||
Studied Microbe: Bifidobacterium
Show/Hide Hierarchy
|
[2] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experimental Species | Human | Experimental Sample | Faeces | |
Disease or Condition | Healthy | |||
Description | The abundance of Bifidobacterium was decreased by Ofloxacin. | |||
Studied Microbe: Bifidobacterium adolescentis
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Bifidobacterium adolescentis was decreased by Ofloxacin (adjusted p-values: 5.04E-06). | |||
The Order in the Taxonomic Hierarchy of the following Microbe(s): Coriobacteriales | ||||
Studied Microbe: Collinsella aerofaciens
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Collinsella aerofaciens was decreased by Ofloxacin (adjusted p-values: 2.73E-07). | |||
The Order in the Taxonomic Hierarchy of the following Microbe(s): Eggerthellales | ||||
Studied Microbe: Eggerthella lenta
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Eggerthella lenta was decreased by Ofloxacin (adjusted p-values: 1.23E-05). | |||
The Order in the Taxonomic Hierarchy of the following Microbe(s): Enterobacterales | ||||
Studied Microbe: Enterobacteriaceae
Show/Hide Hierarchy
|
[4], [5] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experimental Species | Human | Experimental Sample | Faeces | |
Disease or Condition | Healthy | |||
Description | The abundance of Enterobacteriaceae was decreased by Ofloxacin (p < 0.05). | |||
Studied Microbe: Escherichia coli ED1a
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Escherichia coli ED1a was decreased by Ofloxacin (adjusted p-values: 6.88E-06). | |||
Studied Microbe: Escherichia coli IAI1
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Escherichia coli IAI1 was decreased by Ofloxacin (adjusted p-values: 5.04E-06). | |||
The Order in the Taxonomic Hierarchy of the following Microbe(s): Eubacteriales | ||||
Studied Microbe: Clostridium
Show/Hide Hierarchy
|
[4] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experimental Species | Human | Experimental Sample | Faeces | |
Disease or Condition | Healthy | |||
Description | The abundance of Clostridium was decreased by Ofloxacin. | |||
Studied Microbe: Clostridium difficile
Show/Hide Hierarchy
|
[2] | |||
Hierarchy | ||||
Abundance Change | No significant change | |||
Experimental Species | Human | Experimental Sample | Faeces | |
Disease or Condition | Healthy | |||
Description | The abundance of Clostridium difficile was not significantly changed by Ofloxacin. | |||
Studied Microbe: Clostridium perfringens
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Clostridium perfringens was decreased by Ofloxacin (adjusted p-values: 5.51E-07). | |||
Studied Microbe: Peptostreptococcus
Show/Hide Hierarchy
|
[4] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experimental Species | Human | Experimental Sample | Saliva | |
Disease or Condition | Healthy | |||
Description | The abundance of Peptostreptococcus was decreased by Ofloxacin. | |||
The Order in the Taxonomic Hierarchy of the following Microbe(s): Kitasatosporales | ||||
Studied Microbe: Neisseria cocci
Show/Hide Hierarchy
|
[4] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experimental Species | Human | Experimental Sample | Saliva | |
Disease or Condition | Healthy | |||
Description | The abundance of Neisseria cocci was decreased by Ofloxacin (p < 0.05). | |||
The Order in the Taxonomic Hierarchy of the following Microbe(s): Lactobacillales | ||||
Studied Microbe: Enterococcus
Show/Hide Hierarchy
|
[4] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experimental Species | Human | Experimental Sample | Faeces | |
Disease or Condition | Healthy | |||
Description | The abundance of Enterococcus was decreased by Ofloxacin (p < 0.05). | |||
Studied Microbe: Lactobacillus
Show/Hide Hierarchy
|
[2] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experimental Species | Human | Experimental Sample | Faeces | |
Disease or Condition | Healthy | |||
Description | The abundance of Lactobacillus was decreased by Ofloxacin. | |||
Studied Microbe: Lactobacillus paracasei
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Lactobacillus paracasei was decreased by Ofloxacin (adjusted p-values: 1.49E-04). | |||
Studied Microbe: Streptococcus
Show/Hide Hierarchy
|
[5] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experimental Species | Human | Experimental Sample | Faeces | |
Disease or Condition | Healthy | |||
Description | The abundance of Streptococcus was decreased by Ofloxacin. | |||
Studied Microbe: Streptococcus parasanguinis
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Streptococcus parasanguinis was decreased by Ofloxacin (adjusted p-values: 1.40E-06). | |||
Studied Microbe: Streptococcus salivarius
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Streptococcus salivarius was decreased by Ofloxacin (adjusted p-values: 2.25E-05). | |||
The Order in the Taxonomic Hierarchy of the following Microbe(s): Veillonellales | ||||
Studied Microbe: Veillonella parvula
Show/Hide Hierarchy
|
[3] | |||
Hierarchy | ||||
Abundance Change | Decrease | |||
Experiment Method | High-throughput screening | |||
Description | The abundance of Veillonella parvula was decreased by Ofloxacin (adjusted p-values: 5.04E-06). |
Drug Resistance Mutation (DRM) | Top | |||
---|---|---|---|---|
DRM | DRM Info |
Target and Pathway | Top | |||
---|---|---|---|---|
Target(s) | Bacterial DNA gyrase (Bact gyrase) | Target Info | Modulator | [6] |
References | Top | |||
---|---|---|---|---|
REF 1 | Emerging therapies for the treatment and prevention of otitis media. Expert Opin Emerg Drugs. 2006 May;11(2):251-64. | |||
REF 2 | Development of antimicrobial resistance in the normal anaerobic microbiota during one year after administration of clindamycin or ciprofloxacin. Anaerobe. 2015 Feb;31:72-7. | |||
REF 3 | Extensive impact of non-antibiotic drugs on human gut bacteria. Nature. 2018 Mar 29;555(7698):623-628. | |||
REF 4 | Comparative effects of levofloxacin and ofloxacin on the normal oral and intestinal microflora. Scand J Infect Dis. 1997;29(4):383-6. | |||
REF 5 | Effect of oral ofloxacin on fecal bacteria in human volunteers. Antimicrob Agents Chemother. 1987 Jan;31(1):124-5. | |||
REF 6 | Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. |
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.